GenSight Biologics Appoints William Monteith to its Board of Directors

Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

Annual General Meeting on May 29, 2024

GenSight Biologics announces a successful offering for an amount over €9.2 million

GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

GenSight Biologics Announces Its 2024 Financial Calendar

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration